Text Size

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Celldex Therapeutics
ClinicalTrials.gov Identifier:
NCT00458601
First received: April 10, 2007
Last updated: December 10, 2012
Last verified: December 2012
History of Changes
  Purpose

This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.


Condition Intervention Phase
Malignant Glioma
 Drug: CDX-110 with GM-CSF
Drug: temozolomide
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Celldex Therapeutics:

Primary Outcome Measures:
  • Progression-free survival status [ Time Frame: 5.5mo ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability characterized by adverse events (term, grade, frequency). [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Safety and tolerability characterized by physical examinations. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Safety and tolerability characterized by hematologic and metabolic panel (including CBC with differential, electrolytes, BUN, Cr, liver associated enzymes). [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Safety and tolerability characterized by urinalysis. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Safety and tolerability characterized by vital signs. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Immune response; T-cell response to vaccine. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Immune response; antibody response to vaccine. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Immune response; HLA typing. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Overall survival. [ Time Frame: indeterminate ] [ Designated as safety issue: No ]

Enrollment: 82
Study Start Date: August 2007
Estimated Study Completion Date: December 2013
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CDX-110
Maintenance temozolomide plus intradermal injections of CDX-110 with GM-CSF.
 Drug: CDX-110 with GM-CSF
Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF
Other Name: CDX-110 with sargramostim (GM-CSF) (Leukine®)
Drug: temozolomide
Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles , intolerance or progression.
Other Name: Temodar

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.
  • Gross total resection followed by conventional chemoradiation therapy without progression of disease.

Exclusion Criteria:

  • Presence of diffuse leptomeningeal disease or gliomatosis cerebri.
  • Systemic corticosteroid therapy > 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.
  • Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.
  • Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00458601

  Hide Study Locations
Locations
United States, California
Celldex Investigational Site
Orange, California, United States, 92868
Celldex Investigational Site
San Francisco, California, United States, 94143
Celldex Investigational Site
San Francisco, California, United States, 94143-0622
Celldex Investigational Site
Stanford, California, United States, 94305
Celldex Investigational Site
Stanford, California, United States, 94305-5826
United States, Connecticut
Celldex Investigational Site
New Haven, Connecticut, United States, 06510
Celldex Investigational Site
New Haven, Connecticut, United States, 06519
Celldex Investigational Site
New Haven, Connecticut, United States, 06520
United States, Florida
Celldex Investigational Site
Gainesville, Florida, United States, 32610-0277
United States, Illinois
Celldex Investigational Site
Chicago, Illinois, United States, 60611
Celldex Investigational Site
Evanston, Illinois, United States, 60201
United States, Massachusetts
Celldex Investigational Site
Boston, Massachusetts, United States, 02115
United States, Michigan
Celldex Investigational Site
Lansing, Michigan, United States, 48912
Celldex Investigational Site
Saginaw, Michigan, United States, 48604
Celldex Investigational Site
Saginaw, Michigan, United States, 48601
United States, New Jersey
Celldex Investigational Site
Hackensack, New Jersey, United States, 07601
United States, New York
Celldex Investigational Site
Amherst, New York, United States, 14226
Celldex Investigational Site
New York, New York, United States, 10032
Celldex Investigational Site
New York, New York, United States, 10065
United States, North Carolina
Celldex Investigational Site
Durham, North Carolina, United States, 27710
United States, Ohio
Celldex Investigational Site
Cincinnati, Ohio, United States, 45219
Celldex Investigational Site
Cincinnati, Ohio, United States, 45267-0769
Celldex Investigational Site
Cincinnati, Ohio, United States, 45267-0502
Celldex Investigational Site
Cleveland, Ohio, United States, 44106
Celldex Investigational Site
Cleveland, Ohio, United States, 44195
Celldex Investigational Site
Orange Village, Ohio, United States, 44122
Celldex Investigational Site
West Chester, Ohio, United States, 45069-6542
Celldex Investigational Site
Westlake, Ohio, United States, 44145
United States, Pennsylvania
Celldex Investigational Site
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Celldex Investigational Site
Houston, Texas, United States, 77030
Celldex Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Celldex Investigational Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Celldex Investigational Site
Charlottesville, Virginia, United States, 22908
United States, Washington
Celldex Investigational Site
Seattle, Washington, United States, 98195
Sponsors and Collaborators
Celldex Therapeutics
Investigators
Study Director: Thomas Davis, MD Celldex Therapeutics
  More Information

No publications provided

Responsible Party: Thomas Davis, MD, Celldex Therapeutics
ClinicalTrials.gov Identifier: NCT00458601     History of Changes
Other Study ID Numbers: CDX110-003, CDX110-003
Study First Received: April 10, 2007
Last Updated: December 10, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Celldex Therapeutics:
EGFRvIII vaccine temozolomide cancer vaccine immunotherapy

Additional relevant MeSH terms:
Glioblastoma
Glioma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
 Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013